Brief: Prelude, Incyte Sign Exclusive Option Deal To Advance JAK2V617F JH2 Inhibitors For Cancer Therapy
04/11/2025 12:44
Nov 4 (Reuters) - Prelude Therapeutics Inc PRLD.O: PRELUDE THERAPEUTICS ANNOUNCES EXCLUSIVE OPTION AGREEMENT WITH INCYTE TO ADVANCE MUTANT SELECTIVE JAK2V617F JH2 INHIBITORS PRELUDE THERAPEUTICS INC - TO RECEIVE $35 MILLION UPFRONT, $25 MILLION EQUITY INVESTMENT PRELUDE THERAPEUTICS INC - INCYTE TO PURCHASE 6.25 MILLION SHARES OF PRELUDE AT $4.00 EACH PRELUDE THERAPEUTICS: TO GET $100 MILLION IF INCYTE WERE TO EXERCISE OPTION TO BUY PROGRAM PRELUDE THERAPEUTICS: TO GET UP TO $775 MILLION IN ADDITIONAL POTENTIAL MILESTONES PLUS ROYALTIES ON NET SALES Source text: ID:nGNX6Zk0dH Further company coverage: PRLD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview